Alban de La Sabliere

Sanofi SA (ADR) (NYSE: SNY) is actively looking to enter the rare disease drugs segment through an acquisition. The Financial Times reported on Sunday that David Meeker, head of Sanofi's Genzyme specialty care business, suggested that rare disease assets represent potential targets as the...